Stay updated on GM T-cell Therapy in AML/BPDCN Clinical Trial
Sign up to get notified when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.

Latest updates to the GM T-cell Therapy in AML/BPDCN Clinical Trial page
- Check4 days agoChange DetectedAdded Acute lymphoid leukemia and CD4+/CD56+ hematodermic neoplasm to the conditions/MeSH terms. This broadens indexing but does not modify the trial's design, eligibility criteria, interventions, or other essential details.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision changed from v3.4.3 to v3.5.0. The previous revision entry v3.4.3 was removed and a new entry v3.5.0 was added.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision: v3.4.3 added and Revision: v3.4.2 removed; this is a minor metadata update to the page.SummaryDifference0.0%

- Check54 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 with no user-visible content or functionality changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedUI updates add a visible glossary toggle and display updated metadata: Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0; the previous metadata items Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.2%

Stay in the know with updates to GM T-cell Therapy in AML/BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.